1
|
Huang J, Adungo F, Konongoi SL, Inoue S, Zhan L, Sang R, Ashur S, Kwallah AO, Mwau M, Morita K, Yu F. Monoclonal Antibodies for Rift Valley Fever Virus Nucleocapsid: Application in IgG/IgM ELISA for Sero-Diagnosis. Pathogens 2024; 13:582. [PMID: 39057809 PMCID: PMC11279541 DOI: 10.3390/pathogens13070582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Revised: 07/07/2024] [Accepted: 07/11/2024] [Indexed: 07/28/2024] Open
Abstract
INTRODUCTION Rift Valley fever virus (RVFV) belonging to the Phenuiviridae family is responsible for a zoonotic disease called Rift Valley fever (RVF). Currently, RVFV has spread from Africa to Asia, and due to its ability to cause high mortality rates, it has significantly impacted human health and economic development in many societies. Highly specific and sensitive systems for sero-diagnosis of RVFV infection are needed for clinical use. METHOD BALB/c mice were immunized with recombinant RVFV nucleocapsid (rRVFV-N) protein and the spleen cells fused with SP2/0 myeloma cells to create hybridoma cell lines. The secreted monoclonal antibodies (MAbs) were purified and characterized. Enzyme-linked immunosorbent assay (ELISA) systems for the detection of IgG and IgM using the new MAbs were established and evaluated. Serum samples from 96 volunteers and 93 patients of suspected RVF from Kenya were tested compared with the ELISA systems based on inactivated viruses and the rabbit polyclonal antibody. RESULT Three monoclonal antibodies against rRVFV-N protein were established. The performance of the MAb-based sandwich IgG ELISA and the IgM capture ELISA perfectly matched the ELISA systems using the inactivated virus or the polyclonal antibody. CONCLUSIONS Recombinant RVFV-N protein-specific MAbs were developed and they offer useful tools for RVFV studies. The MAb-based ELISA systems for detecting IgG and IgM offer safe and useful options for diagnosing RVFV infections in humans.
Collapse
Affiliation(s)
- Jiansheng Huang
- School of Medicine, Guizhou University, Guiyang 550002, China;
| | - Ferdinard Adungo
- Kenya Medical Research Institute, Nairobi 54840-00200, Kenya; (F.A.); (S.L.K.); (R.S.); (S.A.); (A.o.K.); (M.M.)
| | - Samson Limbaso Konongoi
- Kenya Medical Research Institute, Nairobi 54840-00200, Kenya; (F.A.); (S.L.K.); (R.S.); (S.A.); (A.o.K.); (M.M.)
| | - Shingo Inoue
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4, Sakamoto, Nagasaki 852-8523, Japan; (S.I.); (K.M.)
| | - Lin Zhan
- NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People’s Hospital, Guiyang 550002, China;
- Guizhou Provincial People’s Hospital, Guizhou University, Guiyang 550002, China
| | - Rosemary Sang
- Kenya Medical Research Institute, Nairobi 54840-00200, Kenya; (F.A.); (S.L.K.); (R.S.); (S.A.); (A.o.K.); (M.M.)
| | - Salame Ashur
- Kenya Medical Research Institute, Nairobi 54840-00200, Kenya; (F.A.); (S.L.K.); (R.S.); (S.A.); (A.o.K.); (M.M.)
| | - Allan ole Kwallah
- Kenya Medical Research Institute, Nairobi 54840-00200, Kenya; (F.A.); (S.L.K.); (R.S.); (S.A.); (A.o.K.); (M.M.)
| | - Matilu Mwau
- Kenya Medical Research Institute, Nairobi 54840-00200, Kenya; (F.A.); (S.L.K.); (R.S.); (S.A.); (A.o.K.); (M.M.)
| | - Kouichi Morita
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4, Sakamoto, Nagasaki 852-8523, Japan; (S.I.); (K.M.)
| | - Fuxun Yu
- NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People’s Hospital, Guiyang 550002, China;
- Guizhou Provincial People’s Hospital, Guizhou University, Guiyang 550002, China
| |
Collapse
|
2
|
Yang L, Xu Q, Yang B, Li J, Dong R, Da J, Ye Z, Xu Y, Zhou H, Zhang X, Liu L, Zha Y, Yu F. IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients. BMC Microbiol 2021; 21:351. [PMID: 34922455 PMCID: PMC8683808 DOI: 10.1186/s12866-021-02401-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 11/25/2021] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND The 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) is a current worldwide threat for which the immunological features after infection need to be investigated. The aim of this study was to establish a highly sensitive and quantitative detection method for SARS-CoV-2 IgG antibody and to compare the antibody reaction difference in patients with different disease severity. RESULTS Recombinant SARS-CoV-2 nucleocapsid protein was expressed in Escherichia coli and purified to establish an indirect IgG ELISA detection system. The sensitivity of the ELISA was 100% with a specificity of 96.8% and a 98.3% concordance when compared to a colloidal gold kit, in addition, the sensitivity of the ELISA was 100% with a specificity of 98.9% and a 99.4% concordance when compared to a SARS-CoV-2 spike S1 protein IgG antibody ELISA kit. The increased sensitivity resulted in a higher rate of IgG antibody detection for COVID-19 patients. Moreover, the quantitative detection can be conducted with a much higher serum dilution (1:400 vs 1:10, 1:400 vs 1:100). The antibody titers of 88 patients with differing COVID-19 severity at their early convalescence ranged from 800 to 102,400, and the geometric mean titer for severe and critical cases, moderate cases, asymptomatic and mild cases was 51,203, 20,912, and 9590 respectively. CONCLUSION The development of a highly sensitive ELISA system for the detection of SARS-CoV-2 IgG antibodies is described herein. This system enabled a quantitative study of rSARS-CoV-2-N IgG antibody titers in COVID-19 patients, the occurrence of higher IgG antibody titers were found to be correlated with more severe cases.
Collapse
Affiliation(s)
- Li Yang
- Medical College, Guizhou University, Guiyang, People's Republic of China.
| | - Qiang Xu
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China
| | - Bin Yang
- Medical College, Guizhou University, Guiyang, People's Republic of China.,Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China
| | - Jiayu Li
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China
| | - Rong Dong
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China
| | - Jingjing Da
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China
| | - Zhixu Ye
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China
| | - Yongjie Xu
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China
| | - Hourong Zhou
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China
| | - Xiangyan Zhang
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China.,NHC Key Laboratory of Pulmonary Immunological Diseases (Guizhou Provincial People's Hospital), Guiyang, People's Republic of China
| | - Lin Liu
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China.,NHC Key Laboratory of Pulmonary Immunological Diseases (Guizhou Provincial People's Hospital), Guiyang, People's Republic of China
| | - Yan Zha
- Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China.,NHC Key Laboratory of Pulmonary Immunological Diseases (Guizhou Provincial People's Hospital), Guiyang, People's Republic of China
| | - Fuxun Yu
- Medical College, Guizhou University, Guiyang, People's Republic of China. .,Department of Central Laboratory, Guizhou Provincial People's Hospital, No. 83 Zhongshan Dong Road, Guiyang, 550002, Guizhou Province, People's Republic of China. .,NHC Key Laboratory of Pulmonary Immunological Diseases (Guizhou Provincial People's Hospital), Guiyang, People's Republic of China.
| |
Collapse
|
3
|
Mutantu PN, Ngwe Tun MM, Nabeshima T, Yu F, Mukadi PK, Tanaka T, Tashiro M, Fujita A, Kanie N, Oshiro R, Takazono T, Imamura Y, Hirayama T, Moi ML, Inoue S, Izumikawa K, Yasuda J, Morita K. Development and Evaluation of Quantitative Immunoglobulin G Enzyme-Linked Immunosorbent Assay for the Diagnosis of Coronavirus Disease 2019 Using Truncated Recombinant Nucleocapsid Protein as Assay Antigen. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 18:9630. [PMID: 34574555 PMCID: PMC8469721 DOI: 10.3390/ijerph18189630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 09/04/2021] [Accepted: 09/09/2021] [Indexed: 11/24/2022]
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). Real-time RT-PCR is the most commonly used method for COVID-19 diagnosis. However, serological assays are urgently needed as complementary tools to RT-PCR. Hachim et al. 2020 and Burbelo et al. 2020 demonstrated that anti-nucleocapsid(N) SARS-CoV-2 antibodies are higher and appear earlier than the spike antibodies. Additionally, cross-reactive antibodies against N protein are more prevalent than those against spike protein. We developed a less cross-reactive immunoglobulin G (IgG) indirect ELISA by using a truncated recombinant SARS-CoV-2 N protein as assay antigen. A highly conserved region of coronaviruses N protein was deleted and the protein was prepared using an E. coli protein expression system. A total of 177 samples collected from COVID-19 suspected cases and 155 negative control sera collected during the pre-COVID-19 period were applied to evaluate the assay's performance, with the plaque reduction neutralization test and the commercial SARS-CoV-2 spike protein IgG ELISA as gold standards. The SARS-CoV-2 N truncated protein-based ELISA showed similar sensitivity (91.1% vs. 91.9%) and specificity (93.8% vs. 93.8%) between the PRNT and spike IgG ELISA, as well as also higher specificity compared to the full-length N protein (93.8% vs. 89.9%). Our ELISA can be used for the diagnosis and surveillance of COVID-19.
Collapse
Affiliation(s)
- Pierre Nsele Mutantu
- Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan; (P.N.M.); (P.K.M.)
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan; (M.M.N.T.); (T.N.); (M.L.M.); (K.M.)
- Program for Nurturing Global Leaders in Tropical and Emerging Communicable Diseases, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
| | - Mya Myat Ngwe Tun
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan; (M.M.N.T.); (T.N.); (M.L.M.); (K.M.)
| | - Takeshi Nabeshima
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan; (M.M.N.T.); (T.N.); (M.L.M.); (K.M.)
| | - Fuxun Yu
- Guizhou Provincial People’s Hospital, Guiyang 550002, China;
| | - Patrick Kakoni Mukadi
- Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan; (P.N.M.); (P.K.M.)
- Program for Nurturing Global Leaders in Tropical and Emerging Communicable Diseases, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
- Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
| | - Takeshi Tanaka
- Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; (T.T.); (M.T.); (A.F.); (K.I.)
| | - Masato Tashiro
- Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; (T.T.); (M.T.); (A.F.); (K.I.)
| | - Ayumi Fujita
- Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; (T.T.); (M.T.); (A.F.); (K.I.)
| | - Nobuhiro Kanie
- Department of Infectious Diseases, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; (N.K.); (R.O.)
| | - Ryosaku Oshiro
- Department of Infectious Diseases, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; (N.K.); (R.O.)
| | - Takahiro Takazono
- Department of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; (T.T.); (Y.I.); (T.H.)
| | - Yoshifumi Imamura
- Department of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; (T.T.); (Y.I.); (T.H.)
- Medical Education Development Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
| | - Tatsuro Hirayama
- Department of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; (T.T.); (Y.I.); (T.H.)
| | - Meng Ling Moi
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan; (M.M.N.T.); (T.N.); (M.L.M.); (K.M.)
| | - Shingo Inoue
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan; (M.M.N.T.); (T.N.); (M.L.M.); (K.M.)
| | - Koichi Izumikawa
- Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; (T.T.); (M.T.); (A.F.); (K.I.)
| | - Jiro Yasuda
- Department of Emerging Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan;
| | - Kouichi Morita
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan; (M.M.N.T.); (T.N.); (M.L.M.); (K.M.)
| |
Collapse
|
4
|
Further Characterization of Rio Grande Virus and Potential for Cross Reactivity with Rift Valley Fever Virus Assays. Viruses 2021; 13:v13091719. [PMID: 34578299 PMCID: PMC8471117 DOI: 10.3390/v13091719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 08/17/2021] [Accepted: 08/26/2021] [Indexed: 11/17/2022] Open
Abstract
Phleboviruses (genus Phlebovirus, family Phenuiviridae) are emerging pathogens of humans and animals. Sand-fly-transmitted phleboviruses are found in Europe, Africa, the Middle East, and the Americas, and are responsible for febrile illness and nervous system infections in humans. Rio Grande virus (RGV) is the only reported phlebovirus in the United States. Isolated in Texas from southern plains woodrats, RGV is not known to be pathogenic to humans or domestic animals, but serologic evidence suggests that sheep (Ovis aries) and horses (Equus caballus) in this region have been infected. Rift Valley fever virus (RVFV), a phlebovirus of Africa, is an important pathogen of wild and domestic ruminants, and can also infect humans with the potential to cause severe disease. The introduction of RVFV into North America could greatly impact U.S. livestock and human health, and the development of vaccines and countermeasures is a focus of both the CDC and USDA. We investigated the potential for serologic reagents used in RVFV diagnostic assays to also detect cells infected with RGV. Western blots and immunocytochemistry assays were used to compare the antibody detection of RGV, RVFV, and two other New World phlebovirus, Punta Toro virus (South and Central America) and Anhanga virus (Brazil). Antigenic cross-reactions were found using published RVFV diagnostic reagents. These findings will help to inform test interpretation to avoid false positive RVFV diagnoses that could lead to public health concerns and economically costly agriculture regulatory responses, including quarantine and trade restrictions.
Collapse
|
5
|
Pawęska JT, Jansen van Vuren P, Msimang V, Lô MM, Thiongane Y, Mulumba-Mfumu LK, Mansoor A, Fafetine JM, Magona JW, Boussini H, Bażanow B, Wilson WC, Pepin M, Unger H, Viljoen G. Large-Scale International Validation of an Indirect ELISA Based on Recombinant Nucleocapsid Protein of Rift Valley Fever Virus for the Detection of IgG Antibody in Domestic Ruminants. Viruses 2021; 13:1651. [PMID: 34452515 PMCID: PMC8402881 DOI: 10.3390/v13081651] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2021] [Revised: 08/06/2021] [Accepted: 08/13/2021] [Indexed: 12/21/2022] Open
Abstract
Diagnostic performance of an indirect enzyme-linked immunosorbent assay (I-ELISA) based on a recombinant nucleocapsid protein (rNP) of the Rift Valley fever virus (RVFV) was validated for the detection of the IgG antibody in sheep (n = 3367), goat (n = 2632), and cattle (n = 3819) sera. Validation data sets were dichotomized according to the results of a virus neutralization test in sera obtained from RVF-endemic (Burkina Faso, Democratic Republic of Congo, Mozambique, Senegal, Uganda, and Yemen) and RVF-free countries (France, Poland, and the USA). Cut-off values were defined using the two-graph receiver operating characteristic analysis. Estimates of the diagnostic specificity of the RVFV rNP I-ELISA in animals from RVF-endemic countries ranged from 98.6% (cattle) to 99.5% (sheep) while in those originating from RVF-free countries, they ranged from 97.7% (sheep) to 98.1% (goats). Estimates of the diagnostic sensitivity in ruminants from RVF-endemic countries ranged from 90.7% (cattle) to 100% (goats). The results of this large-scale international validation study demonstrate the high diagnostic accuracy of the RVFV rNP I-ELISA. Standard incubation and inactivation procedures evaluated did not have an adverse effect on the detectable levels of the anti-RVFV IgG in ruminant sera and thus, together with recombinant antigen-based I-ELISA, provide a simple, safe, and robust diagnostic platform that can be automated and carried out outside expensive bio-containment facilities. These advantages are particularly important for less-resourced countries where there is a need to accelerate and improve RVF surveillance and research on epidemiology as well as to advance disease control measures.
Collapse
Affiliation(s)
- Janusz T. Pawęska
- Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham 2131, South Africa;
- Centre for Viral Zoonoses, Department of Medical Virology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa
- Faculty of Health Sciences, School of Pathology, University of Witwatersrand, Johannesburg 2050, South Africa
| | - Petrus Jansen van Vuren
- Australian Centre for Disease Preparedness, CSIRO Health & Biosecurity, Geelong, VIC 3220, Australia;
| | - Veerle Msimang
- Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham 2131, South Africa;
| | - Modu Moustapha Lô
- Laboratoire National de l’Elevage et de Recherches Vétérinaires, Route de Front de Terre, Dakar Hann 2057, BP, Senegal; (M.M.L.); (Y.T.)
| | - Yaya Thiongane
- Laboratoire National de l’Elevage et de Recherches Vétérinaires, Route de Front de Terre, Dakar Hann 2057, BP, Senegal; (M.M.L.); (Y.T.)
| | - Leopold K. Mulumba-Mfumu
- Ministry of Agriculture, Democratic Republic of Congo, Kinshasa 7948, Democratic Republic of the Congo;
- Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Kinshasa, P.O. Box 127, Kinshasa XI, Democratic Republic of the Congo
| | - Alqadasi Mansoor
- Central Veterinary Laboratory, General Directorate of Animal Health & Veterinary Quarantine, Ministry of Agriculture and Irrigation, Sana’a 31220, Yemen;
- Food and Agriculture Organization Office, Sana’a 31220, Yemen
| | - José M. Fafetine
- Veterinary Faculty, Eduardo Mondlane University, Maputo 1103, Mozambique;
| | - Joseph W. Magona
- National Livestock Resources Research Institute, Tororo P.O. Box 96, Uganda;
- Food and Agriculture Organization, Gaborone P.O. Box 54, Botswana
| | - Hiver Boussini
- Direction Generale Des Services Veterinaires, Ministère des Ressources Animales, Ouagadougou 09 BP 907, Burkina Faso;
- African Union Interafrican Bureau for Animal Resources, Nairobi P.O. Box 30786-00100, Kenya
| | - Barbara Bażanow
- Department of Pathology, Faculty of Veterinary Science, University of Environmental and Life Sciences, 50-375 Wroclaw, Poland;
| | - William C. Wilson
- United States Department of Agriculture, Agricultural Research Service, Foreign Arthropod Borne Animal Diseases Research Unit, National Bio- and Agro-Defense Facility, Manhattan, KS 66502, USA;
| | - Michel Pepin
- Agence Française de Sécurité Sanitaire des Aliments, F-69364 Lyon, France;
- VetAgro Sup, Campus Vétérinaire de Lyon, F-69364 Lyon, France
| | - Hermann Unger
- Joint FAO/IAEA Centre for Nuclear Techniques in Food and Agriculture, International Atomic Energy Agency, 1400 Vienna, Austria; (H.U.); (G.V.)
| | - Gerrit Viljoen
- Joint FAO/IAEA Centre for Nuclear Techniques in Food and Agriculture, International Atomic Energy Agency, 1400 Vienna, Austria; (H.U.); (G.V.)
| |
Collapse
|